Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Strong Cash Position at exit 2020

<< Previous

Bullboard Posts

Next >>

Comment by PrivilegedP5000on Nov 16, 2020 12:29pm

156 Views

Post# 31907099

RE:Strong Cash Position at exit 2020

Thanks for the analysis, changing the subject I am curious how management will utilize the 400 million USD tax losses before expiration with the limited resources that they currently have?
in good conscience to minority shareholders should not mgt seek to sell the Company or merge with another entity that currently has taxable income?
can anyone conjure up a scenario where we could even remotely employ our tax loss assets as a stand-alone entity with a 30 million Cdn market cap?
Please, any thoughts?

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale